期刊文献+

盐酸哌罗匹隆治疗精神分裂症的临床疗效观察 被引量:8

盐酸哌罗匹隆治疗精神分裂症的临床疗效观察
原文传递
导出
摘要 目的验证盐酸哌罗匹隆治疗精神分裂症的疗效及安全性。方法将50例精神分裂症患者随机分配到盐酸哌罗匹隆组25例和阿立哌唑组25例进行为期8周的随机双盲对照研究,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效,用副反应记录表评价副反应。结果治疗8周后两组患者PANSS总分及各因子分,均较治疗前明显下降。结论盐酸哌罗匹隆治疗精神分裂症的疗效与阿立哌唑相当,对精神分裂症患者的阳性症状,阴性症状等精神病性症状均有效,不良反应少。 Objective Perospirone Hydrochloride Tablets belonging to atypical antipsychotic drug, to observe perospirone treat schizophrenia efficacy and side effects, we made Aripiprazole Tablets randomized, double -blind control study. Methods Choose our hospital schizophrenia patients were retrospectively 50 cases into groups, include Perospirone groups and Aripiprazole groups every 25 cases. Using random double - blind simulation method, observe the treatment period of 8 weeks. Perospirone Hydrochloride Tablets dose 12 -48mg/d, morning, noon evening three times a day oral, Aripiprazole Tablets dose 10 -30mg/d, morning oral. Adopts PANSS therapeutic evaluation, respectively the 2, 4, 6, 8 weeks in treatment evaluation. With PANSS reduction rate evaluate the efficacy, reduction rate ≥80% was recovery, ≥50% - 〈 80% marked improvement, ≥30% -50% improvement , 〈30% ineffectiveness and ≥50% effective work. Results Our treatment results show that, Perospirone Hydrochloride Tablets of schizophrenics of positive and negative symptoms and depression, anxiety, cognitive function and so on to have obvious curative effect, its safety and tolerability can compare with Aripiprazole Tablets or better than Aripiprazole Tablets. Perospirone Hydrochloride Tablets appear low extrapyramidal adverse reaction, what is a schizophrenia long- term treatment new choice. Conclusions Perospirone groups appear low adverse reaction, it is concerned with it has serotonin (5 - HT) and dopamine D2 receptor antagonist role. Perospirone Hydrochloride Tablets have high affinity binding to 5 - HT and dopamine D2 receptor. Through the antagonism 5 - HT and D2 receptors produces antipsychotic role, to the behavior caused by the dopamine and serotonin system is very effective, causeing low extrapyramidal adverse reaction, for prolactin influence also lighter.
出处 《国际精神病学杂志》 2011年第4期208-210,共3页 Journal Of International Psychiatry
关键词 精神分裂症 药物治疗 Perospirone hydrochloride tablets Aripiprazole tablets Schizophrenia Antipsychotics
  • 相关文献

参考文献3

  • 1中国医药数字图书馆,www.pharmaell.com,多巴胺D2/5HT2拮抗剂精神病药,哌罗匹隆.
  • 2李冠军,李华芳,顾牛范.新型非典型抗精神病药——哌罗匹隆(perospirone)[J].上海精神医学,2001,13(3):163-165. 被引量:19
  • 3Masui T, HonmaH, kondo C, et al. Perospimne therapy in elelerly patien - ts with schizophrenia Seishin Shinkeigaku Zasshi - Psycluatria. NeurdJpn. 2003 ;105:1247 - 1253.

二级参考文献12

  • 1Kazutoyo I, Shin I, Akinori U, et al. Phase I study of perospirone HCl(SM-9018). Clinical Report, 1997, 31(6) : 188
  • 2Mario N. Biotransformation of post-clozapine antipsychotics pharmacological implications. Clin Pharmacokinet, 2000, 38(5) : 393
  • 3Takahashi Y, Kusumi I, Ishikane T, et al. In vivo occupation of dopa mine D1, D2 and serotonin 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm,1998, 105(2-3) : 181
  • 4Tanaka H, Ohno Y, Nakamure M. Localization and pharmacological characterization of [3H] perospirone-binding sites in rat brain.Gen Pharmcal, 1998, 31(1) : 159
  • 5Ishibashi T, Tagashira R, Nakamure M, et al. Effects of perospirone, a novel 5-HT2 and D2 receptor antagonist, on fos protein expression in the rat forebrain. Pharmacol biochem Behav, 1999,63(4) : 535
  • 6Ohno Y, Ishida T, Okuda K, et al. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol, 1997, 49 :213
  • 7Sakamoto H, Matsumoto K, Ohno Y, et al. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent. Pharmacol Biochem Behav,1998, 60(4) : 873
  • 8Ishida T, Okuda K, Ohno Y, et al. Evaluation of perospirone, a novel serotonin-2 an dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced frezzing behavior model in rats. Jph Phamacol, 1996, 72(2) : 119
  • 9Mitsukuni M, Itaru Y, Yukiteru M, et al. Early phase 2 study of a new antipsychotic, perospirone HCl(SM-9018), on scizophrenia.Clinical Report, 1997, 31(6) : 2178
  • 10Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia-a comparative double-blind study with haloperidol. Clin. Eval. , 1997,(24) : 159

共引文献18

同被引文献74

引证文献8

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部